CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Partially HLA-matched Virus Specific T cells (VSTs)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D014777 Virus Diseases NIH 0.12

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 BAT IT: Banked Anti-SARS Cov-2 T Cell Infusions for Treatment of COVID 19

SARS-CoV2-specific T cell lines have been made at Baylor College of Medicine from healthy donors who have made a full recovery from COVID19. The cells are then frozen.These cells will be used to treat patients with confirmed SARS-CoV-2 infection who are at high risk of requiring mechanical ventilation.

NCT04401410 SARS-CoV 2 Viral Infection COVID 19 Biological: Partially HLA-matched Virus Specific T cells (VSTs)
MeSH:Virus Diseases

Primary Outcomes

Description: Primary end point: Treatment-related adverse events (tAE), including GVHD, worsening CRS, and any other treatment-related toxicities by day 14 post-infusion.

Measure: Safety of administering partially HLA-matched SARS-CoVSTs to hospitalized COVID19 patients with high risk of progression to mechanical ventilation.

Time: 14 days post infusion

Secondary Outcomes

Description: Secondary endpoint: Improvement on the WHO Ordinal Scale by day 14 post-infusion.

Measure: Efficacy of anti-COVID19 of administering banked partially HLA-matched SARS-CoVSTs to hospitalized COVID19 patients.

Time: 14 days post infusion

No related HPO nodes (Using clinical trials)